ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding ProPhase Labs, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 33 | 29 | −4 |
| Shares | 2.68M | 2.98M | +302.6K (+11.3%) |
| Value | $1.05M | $1.36M | +$316.5K (+30.2%) |
New holders (6)
Institutions that held ProPhase Labs, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Accretive Wealth Partners, LLC | 250,000 | $114.5K | 0.03% |
| Apollon Wealth Management, LLC | 182,464 | $83.5K | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 14,795 | $7.00K | 0.00% |
| Annex Advisory Services, LLC | 15,000 | $6.87K | 0.00% |
| Nordwand Advisors, LLC | 10,000 | $4.58K | 0.00% |
| Key Financial Inc | 1 | $1 | 0.00% |
Sold out (10)
Institutions that held ProPhase Labs, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Quinn Opportunity Partners LLC | 218,127 | $85.4K |
| Citigroup Inc | 59,468 | $23.3K |
| Virtu Financial LLC | 40,401 | $16.0K |
| United Capital Management of KS, Inc. | 34,700 | $13.6K |
| Cerity Partners LLC | 19,000 | $7.43K |
| Price T Rowe Associates Inc | 16,858 | $7.00K |
| Cubist Systematic Strategies, LLC | 11,767 | $4.60K |
| Principal Securities, Inc. | 10,000 | $3.91K |
| Raymond James Financial Inc | 198 | $77 |
| Barclays PLC | 100 | $39 |